MedTrace Logo

ARDA Software for the Detection of mtmDR

NCT04905459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1012

Last updated 2022-06-06

No results posted yet for this study

Summary

This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.

Conditions

Interventions

DIAGNOSTIC_TEST

ARDA software application

Subject images will be sent to the investigational ARDA software

Sponsors & Collaborators

  • Google LLC.

    collaborator INDUSTRY

  • Optos, PLC

    collaborator INDUSTRY

  • Nikon Corporation

    collaborator UNKNOWN

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • Verily Life Sciences LLC

    lead INDUSTRY

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-05-23
Completion
2022-05-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04905459 on ClinicalTrials.gov